New research sheds fresh light on a trend with serious consequences for the public health-not only in the United States but for patients worldwide.
Sponsor sourcing requirements are diverging from the operating needs and long-term strategies of the major CROs.
Big Pharma is finally making a commitment to partner-based outsourcing.